查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888743

美國尿失禁藥物市場規模、佔有率和趨勢分析報告：按類型、藥物類別、性別、分銷管道、地區和細分市場預測（2025-2033 年）

U.S. Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report By Type (Stress Incontinence, Urge Incontinence), By Drug Class, By Gender, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國尿失禁藥物市場摘要

據估計，2024 年美國尿失禁藥物市值為 15.5 億美元，預計到 2033 年將達到 24.1 億美元。

預計從2025年到2033年，該市場將以5.06%的複合年成長率成長。隨著主要患者群體對先進治療方法的需求不斷成長，美國市場持續擴張。

持續成長的老年人口是推動尿失禁治療需求成長的主要因素，而老年族群膀胱控制障礙的發生率很高。例如，根據StatPearls Publishing於2024年8月發布的報告，美國有1,300萬人患有尿失禁，其中養老院居民的盛行率超過50%，長期居住（超過100天）居民的盛行率高達75%。 53%的居家老年人患有尿失禁。 11%的老年人需要住院治療，出院時仍有23%的老年人有尿失禁。 20-39歲女性的尿失禁盛行率為7-37%，老年女性為9-39%，老年男性為11-34%（其中2-11%的人每天都會出現尿失禁）。在約8000萬女性中，超過60%的人報告有相關症狀。製藥公司正在推出改良藥物，以改善症狀控制並提高患者的用藥依從性。臨床機構的教育工作也鼓勵患者儘早尋求治療。醫療機構正在採用最新的診斷通訊協定，以支持及時啟動治療。抗膽鹼能藥物、BETA3促效劑和聯合治療的日益普及推動了處方量的成長，而患者從症狀控制不佳過渡到積極治療的意願增強，則推動了整體治療接受度的提高。

市場擴張將進一步受到男性和女性對壓力性尿失禁、急性尿失禁和混合性尿失禁認知度提高的推動。例如，Elsevier BV 於 2024 年 5 月發布的一份報告發現，美國成年人每天久坐超過 7 小時，出現急性尿失禁(UUI) 症狀的可能性顯著增加。與久坐時間較短的人相比，女性久坐超過 7 小時會增加壓力性尿失禁 (SUI) 的風險，男性久坐超過 7 小時會增加混合性尿失禁 (MUI) 的風險。產後併發症的增加推動了對個人化藥物的需求。臨床醫生表示，他們越來越傾向於採用微創治療方法來支持長期症狀緩解。製藥公司正在推進開發平臺，以推出耐受性更好的藥物。隨著越來越多的患者尋求便捷的後續照護網路基地台，藥局通路的客流量也不斷成長。數位健康平台正在協助藥物管理，並有助於提高患者對處方治療方案的依從性。以病人為中心的護理路徑的持續實施正在促進產品應用率的提高。

治療領域的成長主要受膀胱控制相關疾病發生率上升的推動，例如肥胖、糖尿病和神經系統疾病。醫院和專科診所正在加強尿失禁護理項目，以簡化病患評估流程。例如，根據美國泌尿系統協會2024年6月發布的報告，美國膀胱過動症（OAB）的盛行率估計為7%至27%，女性為9%至34%。約24%至45%的女性有不同程度的尿失禁，其中20至39歲女性的盛行率為7%至37%，60歲以上女性的盛行率約為9%至39%。老年男性中，OAB的盛行率為11%至34%，其中2%至11%的男性會出現每日症狀。臨床指引強調系統化的治療方案，這增加了藥物需求。泌尿系統和婦科醫生強調早期療育以減少長期併發症。產品創新著重於研發副作用更少、服用更舒適的藥物。市場相關人員正投資教育宣導活動，鼓勵患者及時就醫。隨著越來越多的人重視透過規範的治療方案來改善生活品質，整體醫療服務利用率也不斷提高。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國尿失禁藥物市場變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國尿失禁藥物市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2024 年和 2033 年）
  • 按類型分類的市場規模、預測和趨勢分析（2021 年至 2033 年）
  • 應力性尿失禁
  • 急性尿失禁
  • 溢出性尿失禁
  • 功能性尿失禁
  • 其他

第5章美國尿失禁藥物市場：按藥物類別分類的業務分析

  • 按藥物類別分類的市場佔有率（2024 年和 2033 年）
  • 按藥物類別分類的市場規模、預測和趨勢分析（按藥物類別分類，2021 年至 2033 年）
  • 抗膽鹼能藥物
  • BETA3-腎上腺素受體促效劑
  • α受體阻斷劑
  • 雌激素
  • 去氨加壓素
  • 三環抗憂鬱藥物
  • 其他

第6章美國尿失禁藥物市場：性別業務分析

  • 按性別分類的市場佔有率（2024 年和 2033 年）
  • 性別市場規模、預測與趨勢分析（性別，2021-2033 年）
  • 男性
  • 女士

第7章美國尿失禁藥物市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（按分銷管道分類，2021-2033 年）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Astellas Pharma
    • Urovant Sciences/Sumitomo Pharma America
    • AbbVie
    • Pfizer
    • Merck
    • Sanofi
    • Bayer
    • Eli Lilly
    • Teva Pharmaceutical Industries
    • Johnson &Johnson
Product Code: GVR-4-68040-811-3

U.S. Urinary Incontinence Therapeutics Market Summary

The U.S. urinary incontinence therapeutics market size was estimated at USD 1.55 billion in 2024 and is projected to reach USD 2.41 billion by 2033, growing at a CAGR of 5.06% from 2025 to 2033. The U.S. market is expanding as demand for advanced treatment options rises across key patient groups.

Growth is supported by a steady increase in the elderly population that presents higher rates of bladder control disorders. For instance, August 2024, StatPearls Publishing reported that in the U.S. urinary incontinence affected 13 million individuals; prevalence reached >=50 % in nursing-facility residents and >75 % in long-term (>100 days) residents; 53 % of homebound older adults were incontinent; hospital admission and discharge rates were 11 % and 23 %, respectively; women aged 20-39 showed 7-37 %; older women 9-39 %; older men 11-34 % with 2-11 % daily; and among ~80 million women, >60 % reported symptoms. Manufacturers introduce improved pharmacological agents that offer better symptom control and stronger adherence outcomes. Awareness programs conducted by clinical organizations help patients seek treatment at earlier stages. Healthcare providers adopt updated diagnostic protocols that support timely therapy initiation. Prescription volumes rise through broader use of anticholinergics, beta-3 agonists, and combination regimens. Patient willingness to transition from unmanaged symptoms to active treatment strengthens overall therapeutic uptake.

Market expansion is further influenced by growing recognition of stress, urge, and mixed incontinence across women and men. For instance, May 2024, Elsevier BV reported that in the United States adults who sat for >=7 hours per day had significantly higher odds of experiencing urinary urgency incontinence (UUI) symptoms; women had elevated odds of stress urinary incontinence (SUI) when sitting >=7 h; men had elevated odds of mixed urinary incontinence (MUI) when sitting >=7 h compared with those sitting less. Rising postpartum complications contribute to higher demand for tailored medications. Clinicians report increased preference for minimally invasive options that support long-term symptom relief. Pharmaceutical companies advance R&D pipelines that introduce drugs with improved tolerability profiles. Pharmacy channels record higher footfall as patients seek convenient access points for ongoing therapy. Digital health platforms support medication management and improve follow-through on prescribed regimens. Continuous introduction of patient-centric treatment pathways supports stronger product adoption.

Therapeutic growth is reinforced by rising cases linked to obesity, diabetes, and neurological conditions that impact bladder control. Hospitals and specialty clinics strengthen incontinence care programs that streamline patient evaluation. For instance, June 2024, American Urological Association reported that in the United States the prevalence of overactive bladder (OAB) was estimated at 7 %-27 % in men and 9 %-34 % in women; among women some degree of urinary incontinence was experienced by roughly 24 %-45 %; women aged 20-39 had 7 %-37 %; women older than 60 had approximately 9 %-39 % reporting daily symptoms; older men had rates of 11 %-34 % with daily occurrences in 2 %-11 %. Clinical guidelines highlight structured treatment sequences that elevate demand for pharmacological agents. Urologists and gynecologists emphasize early intervention to reduce long-term complications. Product innovation focuses on agents that deliver fewer side effects and improved dosing comfort. Market players invest in awareness initiatives that encourage patients to seek medical support without delay. Overall utilization increases as more individuals prioritize quality-of-life improvements through regulated therapy plans.

U.S. Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. urinary incontinence therapeutics market report based on type, drug class, gender, and distribution channel:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Stress Incontinence
  • Urge Incontinence
  • Overflow Incontinence
  • Functional Incontinence
  • Others
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Others
  • Gender Outlook (Revenue, USD Million, 2021 - 2033)
  • Male
  • Female
  • Distribution ChannelsOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Gender
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Urinary Incontinence Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Urinary Incontinence Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Stress Incontinence
    • 4.4.1. Stress Incontinence Market, 2021 - 2033 (USD Million)
  • 4.5. Urge Incontinence
    • 4.5.1. Urge Incontinence Market, 2021 - 2033 (USD Million)
  • 4.6. Overflow Incontinence
    • 4.6.1. Overflow Incontinence, 2021 - 2033 (USD Million)
  • 4.7. Functional Incontinence
    • 4.7.1. Functional Incontinence Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Urinary Incontinence Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2033
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 5.4. Anticholinergics
    • 5.4.1. Anticholinergics Market, 2021 - 2033 (USD Million)
  • 5.5. Beta-3 Adrenoceptor Agonists
    • 5.5.1. Beta-3 Adrenoceptor Agonists Market, 2021 - 2033 (USD Million)
  • 5.6. Alpha Blockers
    • 5.6.1. Alpha Blockers Market, 2021 - 2033 (USD Million)
  • 5.7. Estrogen
    • 5.7.1. Estrogen Market, 2021 - 2033 (USD Million)
  • 5.8. Desmopressin
    • 5.8.1. Desmopressin Market, 2021 - 2033 (USD Million)
  • 5.9. Tricyclic Antidepressants
    • 5.9.1. Tricyclic Antidepressants Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Urinary Incontinence Therapeutics Market: Gender Business Analysis

  • 6.1. Gender Market Share, 2024 & 2033
  • 6.2. Gender Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Gender, 2021 to 2033 (USD Million)
  • 6.4. Male
    • 6.4.1. Male Market, 2021 - 2033 (USD Million)
  • 6.5. Female
    • 6.5.1. Female Market, 2021 - 2033 (USD Million)

Chapter 7. U.S. Urinary Incontinence Therapeutics Market: Distribution Channels Business Analysis

  • 7.1. Distribution Channels Market Share, 2024 & 2033
  • 7.2. Distribution Channels Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by distribution channels, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Astellas Pharma
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Urovant Sciences / Sumitomo Pharma America
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. AbbVie
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Pfizer
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sanofi
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Bayer
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Eli Lilly
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Teva Pharmaceutical Industries
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Johnson & Johnson
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 US urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 4 US urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 5 US urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 6 US urinary incontinence therapeutics market, by distribution channels, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. urinary incontinence therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 U.S. urinary incontinence therapeutics market dynamics
  • Fig. 12 U.S. urinary incontinence therapeutics market: Porter's five forces analysis
  • Fig. 13 U.S. urinary incontinence therapeutics market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Stress Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 16 Urge Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 17 Overflow Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 18 Functional Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 21 Anticholinergics market, 2021 - 2033 (USD Million)
  • Fig. 22 Beta-3 Adrenoceptor Agonists market, 2021 - 2033 (USD Million)
  • Fig. 23 Alpha Blockers market, 2021 - 2033 (USD Million)
  • Fig. 24 Estrogen market, 2021 - 2033 (USD Million)
  • Fig. 25 Desmopressin market, 2021 - 2033 (USD Million)
  • Fig. 26 Tricyclic Antidepressants market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Gender market, 2021 - 2033 (USD Million)
  • Fig. 29 Male market, 2021 - 2033 (USD Million)
  • Fig. 30 Male market, 2021 - 2033 (USD Million)
  • Fig. 31 Female market, 2021 - 2033 (USD Million)
  • Fig. 32 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 33 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 34 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 35 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 36 Company categorization
  • Fig. 37 Company market position analysis
  • Fig. 38 Strategic framework